eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants
Rhea-AI Summary
eXoZymes (NASDAQ:EXOZ) priced a public offering of units at $18.00 per unit, each containing two common shares and one warrant. The company sold 592,270 shares and 296,135 warrants, for expected gross proceeds of about $5.33 million before expenses.
The underwriter has a 45-day option for up to 44,420 additional units. Warrants have a $11.24 exercise price, a five-year term, reset and redemption features, and will not be listed. Proceeds will support NCT-related development, R&D, and general corporate purposes.
Positive
- Public offering expected to raise approximately $5.33 million gross proceeds
- Additional capital possible via 45-day option for 44,420 units
- Warrants exercisable at $11.24 may provide future capital inflows
- Proceeds earmarked for NCT opportunities, R&D, and corporate purposes
Negative
- Issuance of 592,270 new shares creates potential shareholder dilution
- Exercise of 296,135 warrants could further increase share count over time
- Warrants will not be listed, limiting secondary-market liquidity
- Warrant exercise price may reset to $0.001 per share under certain future financings
News Market Reaction – EXOZ
In the Jun 8 session, EXOZ declined 7.71%, reflecting a notable negative market reaction. Argus tracked a trough of -9.6% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.6x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Program graduation | Positive | -5.1% | Graduation from Shell GameChanger Accelerator supporting cell-free biomanufacturing advancement. |
| Apr 10 | Strategy discussion | Positive | +2.6% | CCO outlined NCTx strategy and commercialization path on an industry podcast. |
| Mar 31 | FY25 update | Neutral | +12.4% | Reported 2025 expenses, net loss and cash, plus S-3 filing for planned financing. |
| Mar 25 | Earnings call notice | Neutral | +0.4% | Announced upcoming Q4 and full-year 2025 results webinar and investor access details. |
| Mar 18 | Pilot run success | Positive | -2.5% | Successful 100-liter pilot with Cayman Chemical validating NCT purity and scalability. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent EXOZ news has produced mixed reactions, with some positive operational updates sold off while financing and results updates have sometimes traded higher.
Over the past six months, eXoZymes issued several development and financing updates. A March 31, 2026 full-year 2025 update highlighted higher operating investment, a $9.16M net loss and $3.04M cash, and the filing of an S-3 ahead of financing, with shares rising 12.38%. Technical validation of its cell-free biomanufacturing, including a 100-liter pilot run producing over 500 grams of NCT at 99.6% purity, saw modest price declines. Today’s unit offering fits into this ongoing effort to fund NCT and platform development.
Key Terms
warrants financial
common stock purchase warrant financial
over-allotments financial
underwriter financial
prospectus supplement regulatory
registration statement on Form S-3 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOS ANGELES, CA / ACCESS Newswire / June 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the pricing of its public offering of units, each consisting of two shares of common stock and one common stock purchase warrant.
The Company has sold 592,270 shares of common stock together with 296,135 warrants as units, each unit consisting of two shares of common stock and one warrant to purchase one share of common stock. The units will separate immediately upon issuance and all shares of common stock and warrants that comprise the units are being issued as separate securities. The public offering price for a unit is
Total gross proceeds from the offering are expected to be approximately
Each warrant will be exercisable commencing the first anniversary of the date of this offering at an exercise price of
eXoZymes intends to use the net proceeds from this offering to further develop N-trans-caffeoyltyramine (NCT) opportunities associated with our NCT business and products developed under the NCT technology, next in line products, research and development, and for general corporate purposes, working capital purposes and capital expenditures.
MDB Capital is acting as underwriter and sole book-running manager for this offering.
A registration statement on Form S-3 (File No. 333-292781) relating to the securities was filed with the Securities and Exchange Commission ("SEC") and became effective on January 23, 2026. This offering is being made only by means of a prospectus supplement and the accompanying base prospectus that form a part of that registration statement. Copies of the final prospectus supplement, when available, may be obtained from MDB Capital at 14135 Midway Road, Suite G-150, Addison, Texas 75001. The final prospectus supplement will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce highly valuable natural products, via a commercially scalable, sustainable, and abundant alternative: exozymes.
Exozymes are advanced enzymes enhanced through bioengineering and AI to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform abundant feedstock into valuable nutraceuticals and novel medicines.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.
While eXoZymes Inc. has introduced "exozymes" as a scientific concept, the company is not trademarking the concept and views it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and of which it intends to be the market leader.
Learn more at exozymes.com
eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the final prospectus related to the public offering that will be filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.
eXoZymes contact
Lasse Görlitz, VP of Comms & IR
(858) 319-7135
press@exozymes.com
https://www.linkedin.com/company/exozymes
https://x.com/exozymes
https://www.youtube.com/@exozymes
SOURCE: eXoZymes
View the original press release on ACCESS Newswire